NCT03023176View on ClinicalTrials.gov

T-cell And General Immune Response to Seasonal Influenza Vaccine (SLVP018) Year 5, 2013

PHASE4CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

September 30, 2013

Primary Completion Date

November 30, 2013

Study Completion Date

November 30, 2013

Conditions
Influenza
Interventions
BIOLOGICAL

Fluzone® standard IIV3

Influenza Virus Vaccine Suspension (0.5ml) for Intramuscular Injection

BIOLOGICAL

Fluzone® standard IIV3 Pediatric Dose

Influenza Virus Vaccine Suspension (0.25ml) for Intramuscular Injection

All Listed Sponsors
collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

lead

Stanford University

OTHER

NCT03023176 - T-cell And General Immune Response to Seasonal Influenza Vaccine (SLVP018) Year 5, 2013 | Biotech Hunter | Biotech Hunter